tradingkey.logo

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)

ReutersJun 6, 2025 11:12 AM

-

  • OTSUKA SIBEPRENLIMAB PHASE 3 DATA SHOW A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL PROTEINURIA REDUCTION FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

  • OTSUKA: VISIONARY STUDY CONTINUES IN A BLINDED MANNER TO EVALUATE CHANGE IN KIDNEY FUNCTION OVER 24 MONTHS; EXPECTED TO BE COMPLETED IN EARLY 2026

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI